Verastem

Press Releases

November 30, 2020
Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
November 9, 2020
Verastem Oncology Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
October 28, 2020
Verastem Oncology Announces New Data Published in The Lancet Oncology Supports Potential of VS-6766 as Treatment for RAS Mutant Tumors
October 6, 2020
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2020
Verastem Oncology Announces Closing of COPIKTRA® (duvelisib) Sale to Secura Bio
September 16, 2020
Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit
September 14, 2020
Verastem Oncology Announces Investor Conference Call to Discuss Updated Clinical Data in Low-Grade Serous Ovarian Cancer from Phase 1/2 FRAME Study
September 10, 2020
Verastem Oncology to Present at Upcoming Investor Conferences
August 10, 2020
Verastem Oncology Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
August 10, 2020
Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA® (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors
July 6, 2020
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 22, 2020
Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of VS-6766 and Defactinib in Metastatic Uveal Melanoma
May 28, 2020
Verastem Oncology to Present at the Jefferies Virtual Healthcare Conference
May 7, 2020
Verastem Oncology Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress
April 27, 2020
Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the American Association for Cancer Research 2020 Virtual Annual Meeting I
April 23, 2020
Verastem Oncology Appoints John H. Johnson to its Board of Directors
April 21, 2020
Verastem Oncology Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting
April 20, 2020
Verastem Oncology Announces Investor Conference Call to Discuss Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors
April 13, 2020
Verastem Oncology Announces Presentation of Clinical Data from Investigator-initiated RAF/MEK and FAK Combination Study in KRAS Mutant Solid Tumors at the American Association for Cancer Research 2020 Virtual Annual Meeting I
April 7, 2020
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 11, 2020
Verastem Oncology Reports Fourth Quarter and Full-Year 2019 Financial Results
February 28, 2020
Verastem Oncology Announces New Strategic Direction to Advance Its Clinical Development Programs
February 28, 2020
Verastem Oncology Announces $100 Million Private Placement Offering of Common Stock to Premier Life Sciences Investors
January 29, 2020
Verastem Oncology Announces Dosing of First Patient in CSPC’s Chinese Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Follicular Lymphoma
January 8, 2020
Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766
January 6, 2020
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

E-mail Alerts

You may automatically receive Verastem Oncology financial information by e-mail. To choose your options for e-mail notification, please enter your e-mail address below and click Submit.

Investor Contact

getty
John Doyle

VP Investor Relations & Finance
781.292.4279
jdoyle@verastem.com

Joe Rayne

Argot Partners
617.340.6075
joseph@argotpartners.com

Investor Kit